Receptor-Mediated Uptake of Human .ALPHA.1-Acid Glycoprotein into Liver Parenchymal Cells in Mice
-
- MATSUMOTO Kazuaki
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University
-
- NISHI Koji
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University Department of Clinical Pharmacy, Yokohama College of Pharmacy
-
- KIKUCHI Mari
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University
-
- WATANABE Hiroshi
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University Center for Clinical Pharmaceutical Sciences, Kumamoto University
-
- NAKAJOU Keisuke
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University
-
- KOMORI Hisakazu
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University
-
- KADOWAKI Daisuke
- Center for Clinical Pharmaceutical Sciences, Kumamoto University
-
- SUENAGA Ayaka
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University
-
- MARUYAMA Toru
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University Center for Clinical Pharmaceutical Sciences, Kumamoto University
-
- OTAGIRI Masaki
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University Faculty of Pharmaceutical Sciences, Sojo University
Bibliographic Information
- Other Title
-
- Receptor-Mediated Uptake of Human α1-Acid Glycoprotein into Liver Parenchymal Cells in Mice
Search this article
Description
Human α1-acid glycoprotein (AGP), a serum glycoprotein, is thought to have anti-inflammatory effects by a mechanism that is not well understood. In this study, we investigated the pharmacokinetics of AGP in mice using enzymatically modified AGP (AGP with the sialic acids removed, asialo-AGP, and with both sialic acids and galactose removed, agalacto-AGP). It was observed that AGP was eliminated from the circulation slowly, and was mainly taken up by the liver. The elimination of labeled AGP, asialo-AGP and agalacto-AGP from the circulation was suppressed in the presence of excess unlabeled AGP, asialo-AGP and agalacto-AGP, respectively, suggesting the receptor-mediated uptake of these AGPs. Interestingly, the uptake of AGP by the liver competed with agalacto-AGP, but not with asialo-AGP, while agalacto-AGP competed with asialo-AGP. These results suggest that agalacto-AGP binds to at least two types of receptors, namely asialoglycoprotein receptor (ASGPR) and an as yet unidentified receptor that is shared with AGP, and that AGP is directly taken up by the liver through such a receptor and not via ASGPR. These findings help improve our understanding of the clearance mechanism of AGP.<br>
Journal
-
- Drug Metabolism and Pharmacokinetics
-
Drug Metabolism and Pharmacokinetics 25 (1), 101-107, 2010
The Japanese Society for the Study of Xenobiotics
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282680158280960
-
- NII Article ID
- 10027582071
-
- NII Book ID
- AA1162652X
-
- ISSN
- 18800920
- 13474367
-
- PubMed
- 20208393
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
- OpenAIRE
-
- Abstract License Flag
- Disallowed